Full story
FDA clears MEDIFLY Maggots
Cuprina Holdings (Cayman) Limited said on Jun. 15 that its subsidiary received FDA 510(k) clearance for MEDIFLY Maggots, described as medical-grade Lucilia cuprina larvae for maggot debridement therapy (MDT).
“The Food and Drug Administration this week cleared a second carcass-feasting fly species for use in maggot wound therapy, according to an announcement from Cuprina Holdings, a Singapore-based company that has dubbed its new therapeutic larvae MediFly Maggots”
The clearance covers debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds, with application under the supervision of trained healthcare professionals.
Cuprina said the product is cleared based on substantial equivalence to Medical Maggots, the Lucilia sericata product that became the first medicinal maggot cleared by the FDA in 2004.
The company said the U.S. approval gives it commercial rights to both maggot species used in MDT, with Lucilia sericata licensed from Dr. Ronald A. Sherman and Lucilia cuprina through its own MEDIFLY clearance.
Ars Technica reported that the FDA cleared a second fly species for use in maggot wound therapy, naming the new species as Lucilia cuprina, or Australian sheep blowfly.
Two voices on flexibility
Cuprina CEO David Quek said, "We now hold FDA clearance for both species used in MDT, a position no other company holds," framing the dual-species status as an advantage in "one of the world’s most demanding regulatory markets."
Dr. Ronald Sherman, Cuprina’s Medical and Scientific Director, said, "Maggot debridement therapy has earned its place in modern wound care, and adding a second FDA-cleared species strengthens the entire field," linking the clearance to broader MDT strength.
MedPage Today described the FDA-cleared Lucilia cuprina larvae as a non-antibiotic approach indicated for removing dead or infected tissue from non-healing necrotic skin and soft tissue wounds.
The Manila Times said MEDIFLY Maggots is a prescription product applied to a wound under supervision to remove dead and infected tissue and support the body’s natural healing process.
Mugglehead Investment Magazine reported that investors responded to the FDA news by sending Cuprina shares on the Nasdaq up by over 111 per cent on Monday, climbing from around US$3.97 to US$8.41.
Where it may expand next
Cuprina said the MEDIFLY clearance should soon make the product available to wound-care providers across the United States, and it described the FDA 510(k) clearance as a globally recognized regulatory benchmark.
“Singapore-headquartered Cuprina Holdings (Cayman) Ltd (NASDAQ: CUPR) is drawing on nature’s helpers to combat stubborn health issues in innovative ways”
The Manila Times added that Cuprina believes the clearance supports, and may help accelerate, registration pathways for MEDIFLY Maggots in other markets including Saudi Arabia, Hong Kong and mainland China, while noting registrations remain subject to national requirements and timelines.
Mugglehead Investment Magazine similarly said the U.S. approval could potentially speed up approvals in places like Saudi Arabia and mainland China, while Cuprina currently serves Singapore and Hong Kong with MEDIFLY and provides cosmeceutical goods to Malaysia and Australia.
Ars Technica reported that Cuprina appears to be the only company with FDA clearance to sell two species of fly larvae, and it said the company is "abuzz with the potential to dominate the global maggot market."
MedPage Today noted that oversight of maggot products used to be reviewed by the agency's device division, but that the honor now belongs to the Center for Biologics Evaluation and Research.
